[Skip to Content]
[Skip to Content Landing]
Editorial
June 12, 2018

Clinical Trials in Idiopathic Pulmonary Fibrosis in the “Posttreatment Era”

Author Affiliations
  • 1Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, Pennsylvania
JAMA. 2018;319(22):2275-2276. doi:10.1001/jama.2018.6225

The “treatment era” for idiopathic pulmonary fibrosis (IPF) in the United States and other countries was inaugurated in November 2014 following the Food and Drug Administration’s (FDA’s) approval of pirfenidone and nintedanib as treatments for IPF.1 Even the most optimistic pulmonologists may have doubted that such a day would ever arrive, let alone a day when a practicing clinician would have not 1, but 2 medications to treat IPF. The FDA approved pirfenidone and nintedanib on the basis of published studies that showed these therapies slowed the rate of deterioration of forced vital capacity (FVC).2,3

×